BHCM
DMAC icon

Brevan Howard Capital Management’s DiaMedica Therapeutics DMAC Stock Holding History

Brevan Howard Capital Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$127K Buy
18,036
+3,780
+27% +$23.2K ﹤0.01% 1964
2026
Q1 		$96.5K Buy
+14,256
New +$113K ﹤0.01% 2029

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Brevan Howard Capital Management's DMAC Position: Q2 2026 in Review

Brevan Howard Capital Management increased its DiaMedica Therapeutics (DMAC) stake by 27% in Q2 2026, buying an estimated $23.2K and bringing the position to 18,036 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #1964.

Brevan Howard Capital Management first reported a position in DMAC in Q1 2026 and has held it in 2 quarters since. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Brevan Howard Capital Management held 18,036 shares of DiaMedica Therapeutics worth $127K as of Q2 2026.
  • Brevan Howard Capital Management bought 3,780 DiaMedica Therapeutics shares in Q2 2026, an estimated $23.2K.
  • DiaMedica Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1964 holding.
  • Brevan Howard Capital Management first reported a position in DiaMedica Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.